Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 13/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 12/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 12/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 11/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 2/20 | 1.00 |
| ▸ | GCGR | P47871 | 10/20 | 0.77 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.77 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.77 |
| ▸ | FRK | P42685 | 2/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.77 |
| ▸ | GSK3B | P49841 | 2/20 | 0.77 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.77 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.77 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.77 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28904610 | 0.93 | MAPK13 (0.87) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL16497610 | 0.90 | MAPK14 (0.81) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL19868952 | 0.89 | ALOX5 (0.80) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL19868985 | 0.88 | MAPK13 (0.79) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL15075603 | 0.88 | MAPK11 (1.00) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL19868925 | 0.88 | MAPK11 (1.00) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL4553424 | 0.86 | ALOX5 (1.00) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL29103864 | 0.86 | KDM4E (0.83) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL2649978 | 0.85 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12ALOX5 | |
| SCHEMBL4552316 | 0.85 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| US-12421232-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3768267-B1 | BETA-CARBOLINE DERIVATIVES AS DYRK1A INHIBITORS FOR THE TREATMENT OF E.G. DIABETES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| EP-3717475-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220339154-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING INNER EAR HAIR CELLS FOR TREATMENT OF HEARING LOSS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-10-27 | — | — | US | disclosed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | disclosed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, DYRK1A, CSNK1G3 | MAPK14 341/4885MAPK11 485/4885MAPK13 301/4885 |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | MAPK14 229/4885MAPK11 356/4885MAPK13 217/4885 |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | MAP3K20, MAP3K1, PACSIN2 | MAPK14 264/4885MAPK11 324/4885MAPK13 181/4885 |
| US-20220339154-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING INNER EAR HAIR CELLS FOR TREATMENT OF HEARING LOSS | SHH, MYOC, HES1 | MAPK14 4427/4885MAPK11 4197/4885MAPK13 4489/4885 |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, CSNK1E, CSNK1G3 | MAPK14 199/4885MAPK11 247/4885MAPK13 139/4885 |
| US-12421232-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, DYRK1A, CSNK1G3 | MAPK14 341/4885MAPK11 485/4885MAPK13 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.